1. Home
  2. XAIR vs MBIO Comparison

XAIR vs MBIO Comparison

Compare XAIR & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$5.50

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.62

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XAIR
MBIO
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.6M
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
XAIR
MBIO
Price
$5.50
$0.62
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
234.9K
35.0K
Earning Date
06-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
$7,679,000.00
N/A
Revenue This Year
$122.00
N/A
Revenue Next Year
$58.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
107.26
N/A
52 Week Low
$0.33
$0.53
52 Week High
$8.19
$2.19

Technical Indicators

Market Signals
Indicator
XAIR
MBIO
Relative Strength Index (RSI) 76.75 42.39
Support Level $0.64 $0.64
Resistance Level N/A $0.82
Average True Range (ATR) 0.33 0.05
MACD 0.60 -0.01
Stochastic Oscillator 68.12 26.01

Price Performance

Historical Comparison
XAIR
MBIO

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: